Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246753 · ClinicalTrials.gov registry record · Phase 2
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00246753 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 29 participants.
The verdict
NCT00246753, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did not respond to hormone therapy.
Interventions
- DRUG lapatinib ditosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2005-10 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246753
The ClinicalTrials.gov registry entry for NCT00246753 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lapatinib ditosylate is the first listed.
NCT00246753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246753 about?
NCT00246753 is a clinical study titled "Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy". RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did not respond to hormone therapy.
What is the current status of trial NCT00246753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2005-10. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00246753?
The interventions under investigation include: lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00246753?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.